The Lipid lowering and Onset of Renal Disease (LORD) Trial: A randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease

BMC Nephrology

Volumn 9, Issue 1, 2008, Pages

  Fassett, Robert G ^a   Ball, Madeleine J ^b   Robertson, Iain K ^b   Geraghty, Dominic P ^b   Coombes, Jeff S ^c  

^a LAUNCESTON GENERAL HOSPITAL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; PLACEBO; PROTEIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DISEASE CLASSIFICATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATION; KIDNEY FUNCTION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY EXCRETION; ADOLESCENT; CHRONIC KIDNEY FAILURE; DOSE RESPONSE; DRUG ADMINISTRATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HOSPITALIZATION; KIDNEY FUNCTION TEST; MALE; MIDDLE AGED; MULTICENTER STUDY; PROBABILITY; REFERENCE VALUE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROBABILITY; PYRROLES; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 41549125948     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-9-4     Document Type: Article

References (26)

1. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. CA Jones GM McQuillan JW Kusek MS Eberhardt WH Herman J Coresh M Salive CP Jones LY Agodoa, Am J Kidney Dis 1998 32 6 992 999 10.1016/S0272-6386(98)70074-5 9856515
2. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997 349 9069 1857 1863 10.1016/S0140-6736(96)11445-8 9217756
3. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. P Ruggenenti A Perna G Gherardi F Gaspari R Benini G Remuzzi, Lancet 1998 352 9136 1252 1256 10.1016/S0140-6736(98)04433-X 9788454
4. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. AS Levey S Adler AW Caggiula BK England T Greene LG Hunsicker JW Kusek NL Rogers PE Teschan, Am J Kidney Dis 1996 27 5 652 663 10.1016/S0272-6386(96)90099-2 8629624
5. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. S Klahr AS Levey GJ Beck AW Caggiula L Hunsicker JW Kusek G Striker, N Engl J Med 1994 330 13 877 884 10.1056/NEJM199403313301301 8114857
6. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. N Nakao A Yoshimura H Morita M Takada T Kayano T Ideura, Lancet 2003 361 9352 117 124 10.1016/S0140-6736(03) 12229-5 12531578
7. Clinical epidemiology of cardiovascular disease in chronic renal disease. RN Foley PS Parfrey MJ Sarnak, Am J Kidney Dis 1998 32 5 Suppl 3 S112 119 9820470
8. Renal injury of diet-induced hypercholesterolemia in rats. BL Kasiske MP O'Donnell PG Schmitz Y Kim WF Keane, Kidney Int 1990 37 3 880 891 10.1038/ki.1990.62 2313977
9. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. A Whaley-Connell VG DeMarco G Lastra C Manrique R Nistala SA Cooper B Westerly MR Hayden C Wiedmeyer Y Wei, Am J Nephrol 2008 28 1 67 75 10.1159/000109394 17914247
10. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. A Gianella E Nobili M Abbate C Zoja P Gelosa L Mussoni S Bellosta M Canavesi D Rottoli U Guerrini, Am J Pathol 2007 170 4 1165 1177 17392157 10.2353/ajpath.2007.060882
11. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. VG Athyros DP Mikhailidis EN Liberopoulos AI Kakafika A Karagiannis AA Papageorgiou K Tziomalos ES Ganotakis M Elisaf, Nephrol Dial Transplant 2007 22 1 118 127 10.1093/ndt/gfl538 16998214
12. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. M Tonelli L Moye FM Sacks T Cole GC Curhan, J Am Soc Nephrol 2003 14 6 1605 1613 10.1097/01.ASN.0000068461.45784.2F 12761262
13. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. J Shepherd JJ Kastelein V Bittner P Deedwania A Breazna S Dobson DJ Wilson A Zuckerman NK Wenger, Clin J Am Soc Nephrol 2007 2 6 1131 1139 10.2215/CJN.04371206 17942759
14. Statistics in medicine - reporting of subgroup analyses in clinical trials. R Wang SW Lagakos JH Ware DJ Hunter JM Drazen, N Engl J Med 2007 357 21 2189 2194 10.1056/NEJMsr077003 18032770
15. Effect of lipid reduction on the progression of renal disease: a meta-analysis. LF Fried TJ Orchard BL Kasiske, Kidney Int 2001 59 1 260 269 10.1046/j.1523-1755.2001.00487.x 11135079
16. Statins for improving renal outcomes: a meta-analysis. S Sandhu N Wiebe LF Fried M Tonelli, J Am Soc Nephrol 2006 17 7 2006 2016 10.1681/ASN.2006010012 16762986
17. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. LY Agodoa L Appel GL Bakris G Beck J Bourgoignie JP Briggs J Charleston D Cheek W Cleveland JG Douglas, Jama 2001 285 21 2719 2728 10.1001/jama.285.21.2719 11386927
18. Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. P Hovind L Tarnow P Rossing T Teerlink CD Stehouwer JJ Emeis HH Parving, Am J Kidney Dis 2001 38 6 1376 1380 11728978
19. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. LJ Petersen JR Petersen U Talleruphuus ML Moller SD Ladefoged J Mehlsen HA Jensen, Clin Nephrol 2001 55 5 375 383 11393383
20. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. GA Cinotti PC Zucchelli, Nephrol Dial Transplant 2001 16 5 961 966 10.1093/ndt/16.5.961 11328901
21. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. MA van Dijk AM Kamper S van Veen JH Souverijn GJ Blauw, Nephrol Dial Transplant 2001 16 11 2152 2157 10.1093/ndt/16.11.2152 11682660
22. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. H Herlitz K Harris T Risler G Boner J Bernheim J Chanard M Aurell, Nephrol Dial Transplant 2001 16 11 2158 2165 10.1093/ndt/16.11.2158 11682661
23. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. O Samuelsson H Mulec C Knight-Gibson PO Attman B Kron R Larsson L Weiss H Wedel P Alaupovic, Nephrol Dial Transplant 1997 12 9 1908 1915 10.1093/ndt/12.9.1908 9306342
24. The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. GL Bakris P Whelton M Weir A Mimran W Keane E Schiffrin, J Clin Pharmacol 2000 40 8 815 825 10.1177/00912700022009549 10934665
25. Doubling of serum creatinine: is it sensitive and relevant? P Rossing, Nephrol Dial Transplant 1998 13 2 244 246 10.1093/ndt/13.2.244 9509428
26. Study of Heart and Renal Protection (SHARP). C Baigent M Landry, Kidney Int Suppl 2003 84 S207 210 10.1046/j.1523-1755.63.s84.4.x 12694346